16 news items
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN
31 May 24
those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products from third-party payers, including private
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
REGN
31 May 24
obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
REGN
31 May 24
programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products from third
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
REGN
31 May 24
and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; the availability
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
REGN
23 May 24
and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; the availability
wbh1 vv3o
REGN
20 May 24
and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy
r2f3woyqwuy5kmma bksdndsl555kc6nihg5tl0i3bvlz2c
REGN
20 May 24
programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products from third-party
8tmj2r64o4q6oc9f67yn4y7d7prcy8ifes3g4zeh0gqsh18tw89mjtlec12
REGN
13 May 24
, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products from third-party payers, including
inopy2rm5jmsjfacm73f3zdtmz5dmo3vcqg
REGN
8 May 24
impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent
ihlebhuc78raczw5i6 thp2n6ir
REGN
2 May 24
impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; determinations
wt2y2ov 7z07p2h6yyfhpeeu9p9wrowg9vnxz2z
REGN
29 Apr 24
Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement
tiiah3fotujz gmccq522iqcrm59v8
REGN
22 Apr 24
and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products from
cftm5hxjaze7q08pngojsvmibch44v7l8tyrkja694h6uvs65otp7ax9ewvj
REGN
7 Apr 24
, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products from third-party payers
p5krv2m2j6rhe gjiyu
REGN
25 Mar 24
, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products from third-party payers, including
f44embhow
REGN
11 Mar 24
privacy; the availability and extent of reimbursement of Regeneron's Products from third-party payers, including private payer healthcare and insurance
mzgl0ha6aedqks2 ojvk
REGN
8 Mar 24
to patient privacy; the availability and extent of reimbursement of Regeneron's Products (such as EYLEA HD) from third-party payers, including private payer
- Prev
- 1
- Next